Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab

Annals of Hematology

Volumn 89, Issue 10, 2010, Pages 1029-1033

  Chemnitz, Jens Marcus ^a   Uener, Jens ^a   Hallek, Michael ^a   Scheid, Christof ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Follow up; Rituximab; Treatment; TTP

Indexed keywords

AUTOANTIBODY; CD19 ANTIGEN; CORTICOSTEROID; FRESH FROZEN PLASMA; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; MALE; NON FAMILIAL IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADAM PROTEINS; ADULT; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; PLASMA EXCHANGE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77956696359     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0968-3     Document Type: Article

References (25)

1. A Veyradier D Meyer 2005 Thrombotic thrombocytopenic purpura and its diagnosis J Thromb Haemost 3 11 2420 2427 10.1111/j.1538-7836.2005.01350.x 1:STN:280:DC%2BD2Mrms1Cktg%3D%3D 15892859 (Pubitemid 41727157)
2. JL Moake CK Rudy JH Troll MJ Weinstein NM Colannino J Azocar RH Seder SL Hong D Deykin 1982 Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura N Engl J Med 307 23 1432 1435 10.1056/NEJM198212023072306 1:STN:280:DyaL3s%2Fjs1yksA%3D%3D 6813740
3. HM Tsai 1996 Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion Blood 87 10 4235 4244 1:CAS:528:DyaK28XivFGhtb8%3D 8639782
4. M Furlan R Robles B Lammle 1996 Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis Blood 87 10 4223 4234 1:CAS:528: DyaK28XivFGhtb4%3D 8639781
5. M Furlan R Robles M Solenthaler M Wassmer P Sandoz B Lammle 1997 Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura Blood 89 9 3097 3103 1:CAS:528:DyaK2sXivVOntro%3D 9129011
6. GG Levy WC Nichols EC Lian T Foroud JN McClintick BM McGee AY Yang DR Siemieniak KR Stark R Gruppo, et al. 2001 Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura Nature 413 6855 488 494 10.1038/35097008 1:CAS:528:DC%2BD3MXnsFyit70%3D 11586351 (Pubitemid 32938741)
7. HM Tsai EC Lian 1998 Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura N Engl J Med 339 22 1585 1594 10.1056/NEJM199811263392203 1:STN:280:DyaK1M%2Fjt1Sgsw%3D%3D 9828246 (Pubitemid 28536133)
8. M Furlan R Robles M Galbusera G Remuzzi PA Kyrle B Brenner M Krause I Scharrer V Aumann U Mittler, et al. 1998 von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome N Engl J Med 339 22 1578 1584 10.1056/NEJM199811263392202 1:STN:280: DyaK1M%2Fjt1Sgsg%3D%3D 9828245 (Pubitemid 28536132)
9. WR Bell HG Braine PM Ness TS Kickler 1991 Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients N Engl J Med 325 6 398 403 10.1056/NEJM199108083250605 1:STN:280:DyaK3M3oslOnuw%3D%3D 2062331
10. GA Rock KH Shumak NA Buskard VS Blanchette JG Kelton RC Nair RA Spasoff 1991 Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group N Engl J Med 325 6 393 397 10.1056/NEJM199108083250604 1:STN:280:DyaK3M3oslOnug%3D%3D 2062330
11. JE Sadler 2008 Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura Blood 112 1 11 18 10.1182/blood-2008-02-078170 1:CAS:528:DC%2BD1cXotlymu7o%3D 18574040
12. JA Kremer Hovinga SC Meyer 2008 Current management of thrombotic thrombocytopenic purpura Curr Opin Hematol 15 5 445 450 10.1097/MOH. 0b013e328309ec62 18695366
13. JN George 2000 How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Blood 96 4 1223 1229 1:CAS:528: DC%2BD3cXlvF2it7w%3D 10942361
14. George JN, Sadler JE, Lammle B (2002) Platelets: thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program, pp 315-334
15. SK Vesely JN George B Lammle JD Studt L Alberio MA El-Harake GE Raskob 2003 ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood 102 1 60 68 10.1182/blood-2003-01-0193 1:CAS:528:DC%2BD3sXltFemtLY%3D 12637323 (Pubitemid 36759636)
16. J Chemnitz A Draube C Scheid P Staib A Schulz V Diehl D Sohngen 2002 Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab Am J Hematol 71 2 105 108 10.1002/ajh.10204 1:CAS:528:DC%2BD38Xot1Wqu7c%3D 12353309
17. F Fakhouri JP Vernant A Veyradier M Wolf G Kaplanski R Binaut M Rieger F Scheiflinger P Poullin B Deroure, et al. 2005 Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases Blood 106 6 1932 1937 10.1182/blood-2005-03-0848 1:CAS:528:DC%2BD2MXhtVWksLzE 15933059 (Pubitemid 41291703)
18. M Scully H Cohen J Cavenagh S Benjamin R Starke S Killick I Mackie SJ Machin 2007 Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13 Br J Haematol 136 3 451 461 10.1111/j.1365-2141. 2006.06448.x 1:CAS:528:DC%2BD2sXislShtLo%3D 17233847 (Pubitemid 46046304)
19. F Heidel DB Lipka C von Auer C Huber I Scharrer G Hess 2007 Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia Thromb Haemost 97 2 228 233 1:CAS:528: DC%2BD2sXkt1equ7Y%3D 17264951
20. HT Ling JJ Field MA Blinder 2009 Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature Am J Hematol 84 7 418 421 10.1002/ajh.21439 1:CAS:528:DC%2BD1MXpt1eisr0%3D 19507208
21. E Bresin S Gastoldi E Daina D Belotti E Pogliani P Perseghin PR Scalzulli R Paolini R Marceno G Remuzzi M Galbusera 2009 Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies Thromb Haemost 101 233 238 1:CAS:528: DC%2BD1MXjtVyrtLg%3D 19190804
22. N Cooper DM Arnold 2010 The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases Br J Haematol 149 1 3 13(11) 10.1111/j.1365-2141.2010.08076.x 1:CAS:528: DC%2BC3cXltF2ltro%3D 20151975
23. MC Kappers-Klunne P Wijermans R Fijnheer AJ Croockewit B van der Holt JTM de Wolf B Löwenberg A Brand 2005 Splenectomy for the treatment of thrombotic thrombocytopenic purpura Br J Haematol 130 768 776 10.1111/j.1365-2141.2005.05681.x 1:STN:280:DC%2BD2MvkvVGksQ%3D%3D 16115135 (Pubitemid 43906650)
24. B Garvey 2008 Rituximab in the treatment of autoimmune haematological disorders Br J Haematol 141 2 149 169 10.1111/j.1365-2141.2008.07054.x 1:CAS:528:DC%2BD1cXlsV2muro%3D 18318765 (Pubitemid 351406218)
25. JN George RD Woodson JE Kiss K Kojouri SK Vesely 2006 Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders J Clin Apher 21 1 49 56 10.1002/jca.20091 16619232